Northern Trust Corp raised its holdings in GRIFOLS S A/S (NASDAQ:GRFS) by 24.3% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 516,070 shares of the biotechnology company’s stock after buying an additional 100,769 shares during the period. Northern Trust Corp owned 0.08% of GRIFOLS S A/S worth $11,096,000 at the end of the most recent reporting period.
A number of other hedge funds have also modified their holdings of GRFS. UBS Group AG increased its stake in GRIFOLS S A/S by 144.8% in the 1st quarter. UBS Group AG now owns 77,244 shares of the biotechnology company’s stock valued at $1,638,000 after buying an additional 45,686 shares during the last quarter. Royal Bank of Canada increased its stake in GRIFOLS S A/S by 16.3% in the 1st quarter. Royal Bank of Canada now owns 91,769 shares of the biotechnology company’s stock valued at $1,945,000 after buying an additional 12,889 shares during the last quarter. Suntrust Banks Inc. acquired a new stake in GRIFOLS S A/S in the 1st quarter valued at $252,000. BNP Paribas Arbitrage SA increased its stake in GRIFOLS S A/S by 14.3% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 34,055 shares of the biotechnology company’s stock valued at $732,000 after buying an additional 4,255 shares during the last quarter. Finally, Engadine Partners LLP increased its stake in GRIFOLS S A/S by 18.0% in the 2nd quarter. Engadine Partners LLP now owns 2,906,319 shares of the biotechnology company’s stock valued at $62,486,000 after buying an additional 443,386 shares during the last quarter. Hedge funds and other institutional investors own 21.35% of the company’s stock.
Several brokerages have issued reports on GRFS. Zacks Investment Research upgraded shares of GRIFOLS S A/S from a “strong sell” rating to a “hold” rating in a research note on Wednesday, August 1st. BidaskClub upgraded shares of GRIFOLS S A/S from a “strong sell” rating to a “sell” rating in a research note on Saturday, July 28th. Santander raised shares of GRIFOLS S A/S from an “underperform” rating to a “hold” rating in a research report on Tuesday, October 30th. Berenberg Bank raised shares of GRIFOLS S A/S from a “hold” rating to a “buy” rating in a research report on Thursday, October 11th. Finally, Morgan Stanley decreased their price objective on shares of GRIFOLS S A/S from $22.00 to $20.00 and set an “underweight” rating for the company in a research report on Monday, October 1st. Two research analysts have rated the stock with a sell rating, five have assigned a hold rating and three have issued a buy rating to the company. The company currently has an average rating of “Hold” and an average target price of $21.50.
Shares of GRFS opened at $21.18 on Friday. GRIFOLS S A/S has a one year low of $17.47 and a one year high of $25.18. The stock has a market capitalization of $14.52 billion, a PE ratio of 17.72, a PEG ratio of 1.52 and a beta of 1.18. The company has a quick ratio of 1.12, a current ratio of 2.78 and a debt-to-equity ratio of 1.47.
The company also recently disclosed a special dividend, which will be paid on Tuesday, December 11th. Stockholders of record on Monday, December 3rd will be given a $0.2283 dividend. This represents a dividend yield of 2.25%. The ex-dividend date is Friday, November 30th. This is an increase from GRIFOLS S A/S’s previous special dividend of $0.01. GRIFOLS S A/S’s dividend payout ratio (DPR) is 35.45%.
About GRIFOLS S A/S
Grifols, SA, a specialty pharmaceutical company, develops, manufactures, and distributes biological medicines on plasma derived proteins in the United States, Canada, Spain, rest of the European Union, and internationally. The company operates through five segments: Bioscience, Diagnostic, Hospital, Bio Supplies, and Others.
Featured Article: How to Invest in a Bull Market
Receive News & Ratings for GRIFOLS S A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GRIFOLS S A/S and related companies with MarketBeat.com's FREE daily email newsletter.